ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Date
2016
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
BENTHAM SCIENCE PUBL LTD
Series Info
CURRENT MEDICINAL CHEMISTRY;Volume: 23 Issue: 2 Pages: 142-160
Scientific Journal Rankings
Abstract
ROS1 is a pivotal transmembrane receptor protein tyrosine kinase which regulates several cellular processes like apoptosis, survival, differentiation, proliferation, cell migration, and transformation. There is increasing evidence supporting that ROS1 plays an important role in different malignancies including glioblastoma, colorectal cancer, gastric adenocarcinoma, inflammatory myofibroblastic tumor, ovarian cancer, angiosarcoma, and non small cell lung cancer; thus, ROS1 has become a potential drug discovery target. ROS1 shares about 49% sequence homology with ALK primary structure; therefore, wide range of ALK kinase inhibitors have shown in vitro inhibitory activity against ROS1 kinase. After Crizotinib approval by FDA for the management of ALK-rearranged lung cancer, ROS1-positive tumors have been focused. Although significant advancements have been achieved in understanding ROS1 function and its signaling pathways plus recent discovery of small molecules modulating ROS1 protein, a vital need of medicinal chemistry efforts is still required to produce selective and potent ROS1 inhibitors as an important therapeutic strategy for different human malignancies. This review focuses on the current knowledge about different scaffolds targeting ROS1 rearrangements, methods to synthesis, and some biological data about the most potent compounds that have delivered various scaffold structures.
Description
Accession Number: WOS:000372330600004
Keywords
GLIOBLASTOMA, POTENT, ALK, RECEPTOR, THERAPEUTIC TARGET, BIOLOGICAL EVALUATION, C-ROS, PROTEIN-TYROSINE-PHOSPHATASE, CELL LUNG-CANCER, ANAPLASTIC LYMPHOMA KINASE, translocation, cancer, inhibitor, receptor tyrosine kinase, ROS1 kinase